Steven Leonard Chapman Sells 6,980 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 6,980 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00. Following the completion of the transaction, the chief executive officer now owns 185,182 shares in the company, valued at $27,795,818.20. This represents a 3.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, April 28th, Steven Leonard Chapman sold 6,203 shares of Natera stock. The stock was sold at an average price of $152.18, for a total value of $943,972.54.
• On Monday, April 21st, Steven Leonard Chapman sold 1,664 shares of Natera stock. The shares were sold at an average price of $145.55, for a total value of $242,195.20.
• On Monday, March 31st, Steven Leonard Chapman sold 9,563 shares of Natera stock. The shares were sold at an average price of $138.41, for a total transaction of $1,323,614.83.
• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The shares were sold at an average price of $146.03, for a total value of $978,693.06.
• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80.

Natera Trading Up 0.5 %

Shares of NTRA stock traded up $0.72 during trading hours on Monday, hitting $157.38. 883,861 shares of the company were exchanged, compared to its average volume of 1,381,444. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average of $146.87 and a 200 day moving average of $154.84. The firm has a market cap of $21.28 billion, a PE ratio of -89.42 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Several large investors have recently made changes to their positions in NTRA. LRI Investments LLC purchased a new position in Natera in the fourth quarter valued at about $29,000. Blue Trust Inc. boosted its holdings in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc grew its position in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares in the last quarter. Finally, ORG Partners LLC acquired a new stake in Natera during the 1st quarter valued at $32,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of research analyst reports. Royal Bank of Canada started coverage on Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th. Guggenheim raised their price target on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, January 17th. StockNews.com upgraded Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. Finally, Piper Sandler increased their price target on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $175.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.